A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Brain metastases; Malignant melanoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 26 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 10 Jun 2017 Biomarkers information updated